Micro Tech Nanjing Co Ltd

Micro-Tech (Nanjing) Co., Ltd. is a company that, along with its subsidiaries, researches, develops, manufactures, and sells minimally invasive medical devices in China and internationally. Its product portfolio includes digestive endoscopy products such as ESD devices (e.g., electric flushing device, harmony/GT gold clip, gold/titanium knife, pull clamp, three-arm clap, hemostatic titanium forceps, injection needle, vascular clamp, spray pipe, electric oil, and indigo carmine mucosal staining agent) and ERCP devices (e.g., biliary duct drainage tube, nasobiliary drainage catheter, stone removal balloon, stone retrieval basket, level 3 balloon dilation catheter, guide wire, ruyi knife, and eyemax insights). The company also provides hemostasis products (e.g., bandage and star king clip), dilation and biopsy products (e.g., covered biliary stent, biliary stent, intestinal stent kit with biopsy access, intestinal stent, covered intestinal stent, segmented esophageal stent system, and covered esophageal stent kit), EUS products (e.g., ultrasonic water bag and ultrasonic needle), cell brush, and net ring toss, cleaning brush, mouth pad, and foreign body forceps. Additionally, it offers interventional radiology and surgical devices. Founded in 2000, the company is headquartered in Nanjing, China.

688029.CG▲

Micro-Tech Nanjing Plans Cash Dividend of 5 Yuan per 10 Shares

Micro-Tech Nanjing announced on August 26 that it plans to distribute a cash dividend of 5 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 93.3 million yuan, accounting for 30.75% of the net profit attributable to the parent company in the 2026 interim consolidated financial statements. In the first half of 2026, Micro-Tech Nanjing achieved revenue of 1.728 billion yuan and net profit attributable to the parent company of 303 million yuan.

688029.CG ▲

财中社·24dRead more →

688029.CG▼

Nanwei Medical's first-half net profit falls 16.5% year on year; plans dividend of 5 yuan per 10 shares

Nanwei Medical disclosed its semi-annual report on August 26. In the first half of 2026, the company achieved operating revenue of 1.728 billion yuan, up 10.39% year on year, but net profit attributable to shareholders of the listed company was 303 million yuan, down 16.5% year on year, with basic earnings per share of 1.63 yuan. The company plans to distribute a cash dividend of 5.0 yuan, tax included, for every 10 shares. During the reporting period, the company had a relatively high exposure to foreign currency funds and foreign currency monetary assets. Affected by the appreciation of the renminbi, the translation of foreign currency asset exposure resulted in an exchange loss of 83 million yuan, which had a short-term negative impact on first-half profit.

688029.CG ▼

证券时报·24dRead more →